Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Establishing a New Gene Therapy Drug Process Development Building and Expanding Product Facilities in Texas, USA
ADL Bionatur Solutions, a company specialized in the research and development of health, cosmetic and beauty products, services and industrial fermentation production, reported financial results for the third quarter and first nine months of 2019.
Leading Patient Experience Platform Advances Company’s Market Position
Strategic investment in the US-based company complements Advanced MedTech’s non-invasive product portfolio and strengthens its leadership in urology and stone management
Merck plunked down $576 million to acquire San Diego-based Calporta to gain access to preclinical TRPML1 agonists that are seen as potential treatments for neurodegenerative disorders such as Alzheimer’s or Parkinson’s.
Over 15,000 patients worldwide already treated with Letermovir to prevent Cytomegalovirus (CMV) infection and disease in allogeneic stem cell transplantation
Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, announced it has raised an additional $6.5M in a Series B-3 financing round.
Secarna Pharmaceuticals, a new breed of biopharmaceutical company focusing on the discovery and development of antisense oligonucleotide therapies to address challenging or previously undruggable targets, announced that the Company has completed a financing round, which was open only to existing investors.
Expedeon AG announces the signing of an agreement with Abcam plc, Cambridge, UK, to sell its proteomics and immunology business activities for a cash payment of EUR 120 million.
The merged company will be led by David Domzalski, current chief executive officer of Foamix. It will be headquartered in New Jersey.